Press release Communiqué de presse

Share the news     Partagez les nouvelles

Press release Communiqué de presse

October 23, 2018 23 October, 2018

Sernova-HemAcure Consortium to Present Achievements in Development of a Regenerative Medicine Approach to Treat Hemophilia A

Source: Sernova Corp

October 23, 2018 6:00 a.m. EDT

LONDON, ONTARIO –October 23, 2018 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) a regenerative medicine company, announces that Dr. Philip Toleikis, Sernova’s President and CEO, along with the additional Horizon 2020 HemAcure Consortium Leaders, will present an overview of key achievements in developing a novel cell-based therapy for the treatment of Hemophilia A, in a publicly accessible webinar.

The webinar will include an introduction to the consortium, an overview of bleeding disorders with a focus on Hemophilia A, the innovative therapeutic approach HemAcure is developing as well as results and achievements to date. Participants are welcome to submit their questions during the webinar through the Q&A section. Questions that are left unanswered due to time constraint will be collected and answered in a written follow-up published on the HemAcure website.

“Sernova is proud to be amongst the innovators participating in this product development program involving Sernova’s platform technologies with the goal to treat hemophilia A patients. HemAcure is another great opportunity for Sernova to collaborate with international experts to advance next-generation regenerative medicine therapies,” stated Dr. Philip Toleikis, President and CEO of Sernova.

Webinar: Results in Fighting Haemophilia A Date/Time: Thursday October 25, 2018, 4:00 pm CEST (10:00 am ET) Speakers: Dr. Joris Braspenning (University Hospital Würzburg, Germany), Coordinator Prof. Dr. Antonia Follenzi (Università del Piemonte Orientale "Amedeo Avogadro,” Italy) Prof. Dr. Alexandra Stolzing (Loughborough University, UK) Dr. Philip Toleikis (Sernova Corp, Canada) Dipl.-Ing. Martin Zierau (Grünewald GmbH & Co. KG, Germany)

Host: Dr. Gabriele Wagner (ARTTIC, Germany)

To sign up for the Webinar, please visit bit.ly/2J63NYO or follow the instruction provided under Project News at www.hemacure.eu

The webinar will be made available on ARTTIC's YouTube channel, HemAcure’s website and Sernova’s website shortly after the event.

About HemAcure

The overall objective of the HemAcure project is to develop and refine the tools and technologies for a novel ex vivo prepared cell-based therapy to treat the bleeding disease, hemophilia A (caused by a genetic deficiency in clotting factor VIII (FVIII)) that should ultimately lead to improved quality of life of the patients. The European Union's Horizon 2020 research and innovation program has awarded approximately €5.5 million (CDN$8.5) to support the project. International consortium members include the University Hospital Wuerzburg (Coordinating Institute), Germany, IMS - Integrierte Management, Heppenheim, Germany, Università del Piemonte Orientale “Amedeo Avogadro,” Novara, Italy, Loughborough University, Loughborough, United Kingdom, ARTTIC International Management Services, Munich, Germany and Sernova Corp., London, Ontario, Canada. The Consortium has been working together to provide sets of design and manufacturing protocols, based on current European GMP regulations to prepare an Investigational Medicinal Product Dossier (IMPD) for an Investigational Medicinal Product (IMP), composed of therapeutic cells and an implantable medical device (Sernova’s Cell Pouch™). For more information, visit www.hemacure.eu

About Sernova’s Cell Pouch™ Technologies

The Cell Pouch is a novel, proprietary, scalable, implantable macroencapsulation device for the long-term survival and function of therapeutic cells (donor, proprietary stem cell- derived cells and xenogeneic cells) which then release proteins and/or hormones as required to treat disease. The device, designed to eliminate concerns of fibrosis upon implantation, incorporates with tissue forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells. The device with therapeutic cells has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for the survival of insulin-producing cells in humans.

About Sernova Corp

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact:

Dominic Gray, Corporate Communications Tel: (519) 858-5126 Dominic.Gray@sernova.com www.sernova.com

Philip Toleikis, Ph.D., President and CEO Tel: (519) 858-5184 info@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778 ray@raymatthews.ca www.raymatthews.ca

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials and that Sernova will be able to raise additional capital to fund its clinical programs including its planned US FDA clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.